Drug · Other
Triptorelin
CI-DRUG-00000702Explore in graph →CHEMBL1201334 Approved
Regulatory
Approvals (8)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as TRELSTAR (DIN 02412322) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Oct 16, 2013 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as DECAPEPTYL (DIN 02389282) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Aug 9, 2012 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as TRELSTAR (DIN 02243856) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Dec 15, 2005 | health-canada-dpd |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 13 | 9 | 22 | 58 | 8 | CA, US | Jun 15, 2000 | 1997-04 |
| Malignant Prostate Neoplasm | Approved | Phase 4 | 9 | 6 | 13 | 31 | 3 | US | Jun 15, 2000 | 1997-04 |
| Malignant Breast Neoplasm | Phase3 | Phase 3 | 1 | 1 | 6 | 12 | 0 | — | — | 2003-08 |
| Hodgkin Lymphoma | Phase Not Stated | N/A | 0 | 0 | 0 | 1 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (63)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02005887 | TRial on the Endocrine Activity of Neoadjuvant Degarelix(TREND) | completed | Phase 2 | 51 | ETOP IBCSG Partners FoundationNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06513962 | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | recruiting |